𝔖 Bobbio Scriptorium
✦   LIBER   ✦

(−)-FR182877 Is a Potent and Selective Inhibitor of Carboxylesterase-1

✍ Scribed by Gregory C. Adam; Christopher D. Vanderwal; Erik J. Sorensen; Benjamin F. Cravatt

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
159 KB
Volume
42
Category
Article
ISSN
0044-8249

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

(−)-FR182877 Is a Potent and Selective I
(−)-FR182877 Is a Potent and Selective Inhibitor of Carboxylesterase-1
✍ Gregory C. Adam; Christopher D. Vanderwal; Erik J. Sorensen; Benjamin F. Cravatt 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

Natural products constitute a rich source of structurally diverse compounds that display exceptional biochemical and cellular activities. Although many natural products bind reversibly to their protein targets to alter protein-protein interactions and/or catalytic activity, others produce their bi

Pharmacological profile of LY301317, a p
Pharmacological profile of LY301317, a potent and selective 5-HT1A agonist
✍ Mary C. Wolff; Mark J. Benvenga; David O. Calligaro; Ray W. Fuller; Jaswant S. G 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

LY301317 ((4r)-(-)-4-(dipropylamino)-6-(5-oxazolinyl)-1, 3,4,5-tetrahydrobenz[c,d]indole) has high affinity for the 5-HT 1A receptor and weak affinity for the 5-HT 1D and histamine-H 1 receptors. No significant affinity was found for the other amine receptors studied. In rats, LY301317 produced pote

A novel thiazolidinone herbicide is a po
A novel thiazolidinone herbicide is a potent inhibitor of glucose incorporation into cell wall material†
✍ Sharples, Kate R.; Hawkes, Tim R.; Mitchell, Glynn; Edwards, Lucretia S.; Langfo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## phenyl-4-thiazolidinone (compound 1), a representative of a novel class of thiazolidinone herbicides, shows potential for the pre-emergence control of grasses and smallseeded broad-leaved weeds in crops such as soyabean. This compound powerfully inhibited the growth and lateral branching of the

A Phase III trial comparing anastrozole
A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
✍ Aman U. Buzdar; Stephen E. Jones; Charles L. Vogel; Janet Wolter; Paul Plourde; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

The trial was randomized, double blind for anastrozole, open label for for the Arimidex Study Group megestrol acetate, parallel group, and multicenter. Patients were randomly assigned to receive anastrozole, 1 mg (n Å 128); anastrozole, 10 mg (n Å 130); or